Sorry, I don't understand. Please try again

Latest news

Sorry, I don't understand. Please try again

Filters

15 Results

Selected

Clear All

Immunology

Warm autoimmune hemolytic anemia (wAIHA) research presented by Johnson & Johnson highlights profound disease burden and unmet need for targeted treatment options

December 9, 2024
United States
Immunology

Nipocalimab demonstrates significant clinical improvement in disease activity and IgG reduction in Phase 2 Sjögren’s disease study

November 14, 2024
United States
Immunology

Nipocalimab is the first and only investigational therapy granted U.S. FDA Breakthrough Therapy Designation for the treatment of adults living with moderate-to-severe Sjögren’s disease

November 11, 2024
United States
Neuroscience

Nipocalimab demonstrates sustained disease control in adolescents living with generalized myasthenia gravis in Phase 2/3 study

October 15, 2024
United States
Immunology

Johnson & Johnson seeks first approval of nipocalimab to treat broadest population living with antibody positive generalized myasthenia gravis

August 29, 2024
United States
Immunology

Johnson & Johnson showcases innovation and leadership in rheumatology at EULAR 2024 Congress

30 abstracts highlight the company’s robust portfolio and commitment to improving outcomes for patients with immune-mediated diseases

Features positive results from a Phase 2 study of nipocalimab in Sjögren’s disease as a late-breaking oral presentation

June 4, 2024